Literature DB >> 8532904

Radiotherapy for T2 and T3 carcinoma of the bladder: the influence of overall treatment time.

W De Neve1, M L Lybeert, C Goor, M A Crommelin, J G Ribot.   

Abstract

The influence of overall treatment time on local control rate was studied on a group of 147 patients with muscle invasive T2 or T3 transitional cell carcinoma of the urinary bladder. All patients received external radiotherapy at the Catharina Hospital, Eindhoven, The Netherlands between January 1974 and December 1984. Patients treated with overall treatment times shorter than 75 days (n = 92) were irradiated during a continuous course; all but one patient, with overall treatment times of 75 days or more (n = 55), received split-course radiotherapy. Actuarial local relapse-free probability at 3 years (LRFP3) was computed from the onset of radiotherapy. LRFP3 proved to be dependent on overall treatment time. For T2 stage, LRFP3 was 80 +/- 18% (n = 5) and 54 +/- 13% (n = 13) for overall times between 15-44 and 45-74 days, respectively, 36 +/- 14% (n = 11) for overall times between 75 and 104 days and 64 +/- 15% (n = 11) for overall times longer than 105 days. For T3 stage, LRFP3 was 33 +/- 19% (n = 6) and 48 +/- 10% (n = 25) for overall times between 15-44 and 45-74 days, respectively, 25 +/- 14% (n = 12) for overall times between 75 and 104 days and 22 +/- 14% (n = 9) for overall times longer than 105 days. The figures between brackets are numbers of patients relapsing within 3 years or at risk of relapse during at least 3 years. Patients who died without local relapse before 3 years were censored. We have reasons to believe that patient selection bias leads to overestimation of LRFP3 for the split-course radiotherapy in retrospective studies where the 'intention to treat' cannot be recalled. This retrospective study suggests that prolonging overall time of radiotherapy has an effect on local control in T2 and T3 transitional cell carcinoma of the urinary bladder. Local control was the worst for patients treated by split-course radiotherapy with a gap of approximately one month. Local control was not further decreased (and seemed even improved) by longer gaps, but this observation is possibly biased as explained in the discussion section. For patients treated by continuous course radiotherapy we could not find a difference in local control rates between patients treated with overall times of 44 days or less and those treated with overall times of 45-74 days.

Entities:  

Mesh:

Year:  1995        PMID: 8532904     DOI: 10.1016/0167-8140(95)01586-6

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  12 in total

1.  Compliance to the prescribed overall treatment time (OTT) of curative radiotherapy in normal clinical practice and impact on treatment duration of counteracting short interruptions by treating patients on Saturdays.

Authors:  M Maciá I Garau; J Solé Monné; M J Cambra Serés; C Monfà Binefa; M Peraire Llopis
Journal:  Clin Transl Oncol       Date:  2009-05       Impact factor: 3.405

2.  Muscle-invasive bladder cancer treated with TURB followed by concomitant boost with small reduction of radiotherapy field with or without of chemotherapy.

Authors:  Jadwiga Nowak-Sadzikowska; Tomasz Skóra; Bogumiła Szyszka-Charewicz; Jerzy Jakubowicz
Journal:  Rep Pract Oncol Radiother       Date:  2015-09-29

Review 3.  Radio-chemotherapy for bladder cancer: Contribution of chemotherapy on local control.

Authors:  George A Plataniotis; Roger G Dale
Journal:  World J Radiol       Date:  2013-08-28

4.  Management of invasive bladder cancer in patients who are not candidates for or decline cystectomy.

Authors:  Arjun Balar; Dean F Bajorin; Matthew I Milowsky
Journal:  Ther Adv Urol       Date:  2011-06

Review 5.  Bladder-sparing approaches to invasive disease.

Authors:  Jason A Efstathiou; Anthony L Zietman; Donald S Kaufman; Niall M Heney; John J Coen; William U Shipley
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

6.  Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin: report of Southwest Oncology Group Trial 8733.

Authors:  Celestia S Higano; Catherine M Tangen; Wael A Sakr; James Faulkner; Saul E Rivkin; Frederick J Meyers; Maha Hussain; Laurence H Baker; Kenneth J Russell; E David Crawford
Journal:  Cancer       Date:  2008-05-15       Impact factor: 6.860

Review 7.  Combined chemotherapy and external beam radiotherapy for transitional cell carcinoma of the bladder.

Authors:  Ronald D Ennis
Journal:  Curr Oncol Rep       Date:  2004-05       Impact factor: 5.075

8.  Concurrent chemoradiotherapy improves survival outcome in muscle-invasive bladder cancer.

Authors:  Sang Jun Byun; Jin Hee Kim; Young Kee Oh; Byung Hoon Kim
Journal:  Radiat Oncol J       Date:  2015-12-30

9.  Outcome following radical cystectomy and bladder-preservation therapy in patients with invasive carcinoma of urinary bladder.

Authors:  B S Yadav; S Ghoshal; S C Sharma
Journal:  Indian J Urol       Date:  2008-01

10.  GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON.

Authors:  P J Hoskin; A Sibtain; F M Daley; G D Wilson
Journal:  Br J Cancer       Date:  2003-10-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.